Quantum Leap Energy and South Africa’s Nuclear Energy Corporation (Necsa) have established a binding commercial framework for a proposed high-assay low-enriched uranium production venture at Pelindaba. Announced by parent company ASP Isotopes on 15 October, the Heads of Agreement sets out how the partners intend to develop, finance, construct and operate test and commercial facilities, without establishing that uranium enrichment production has begun.
A subsidiary of Quantum Leap Energy signed the agreement with Necsa, the South African state-owned nuclear organisation. The proposed venture would be owned approximately 80% by Quantum Leap Energy and 20% by Necsa, with the private sector partner leading operations and the arrangement of capital. Necsa would provide access to its nuclear site, safeguards expertise and assistance with the relevant licensing and regulatory processes.
Pelindaba is an established South African nuclear research centre and the headquarters of Necsa. Its facilities include the SAFARI-1 research reactor and infrastructure associated with the country’s historical nuclear research activities. The partners intend to use the site and available expertise as a foundation for a further industrial development, although previous nuclear operations do not remove the need for approvals specific to the proposed enrichment facility.
High-assay low-enriched uranium, or HALEU, contains more than 5% but less than 20% uranium-235 by mass. The concentration is higher than that normally used by existing large commercial light-water reactors, which generally use fuel enriched below 5%. Several advanced reactor designs propose HALEU to meet particular reactor core and operating requirements.
Uranium enrichment changes the relative concentration of uranium isotopes, but a commercial nuclear fuel supply chain extends beyond that stage. Material also has to be prepared and fabricated into the fuel form required by the reactor customer, and its production, transport and use must meet applicable technical, safeguards and regulatory requirements.
Demand for HALEU has become an important consideration for advanced reactor developers because access to qualified fuel can affect whether demonstration and commercial projects proceed as planned. A supply agreement may give a developer a route to obtain future material, but it is not equivalent to the availability of manufactured and accepted fuel.
Quantum Leap Energy has previously secured offtake arrangements with TerraPower, an advanced nuclear reactor developer. ASP Isotopes says those agreements cover HALEU expected from the South African venture. No delivery quantity, price, date or detailed contractual conditions have been disclosed in the October announcement, so the agreements cannot be treated as evidence of production or a confirmed initial shipment.
The Heads of Agreement follows a memorandum of understanding signed in November 2024 and a pre-implementation services contract entered into in February 2026. Those earlier arrangements established the basis for preparatory work and the development of the partnership; the October document adds an intended commercial structure and allocation of responsibilities.
Initial site preparations have progressed. ASP Isotopes says a test bench facility was previously constructed at Pelindaba and that refurbishment of the infrastructure housing it is under way. The statement does not confirm that the bench is currently operating on uranium-235, or that it has demonstrated an enrichment process capable of supplying commercial quantities of HALEU.
A particularly important limitation appears in ASP Isotopes’ own announcement: the company says its enrichment technologies have not yet been applied to uranium-235, and it has not received approval to test them with uranium-235 except for activities contemplated by its services agreement with Necsa. That qualification remains relevant despite the binding commercial terms and access to an established nuclear site.
During July 2026, Quantum Leap Energy received ministerial permission in South Africa relating to the acquisition, possession, use, disposal and transport of source material and specified nuclear-related equipment and technology for activities at Pelindaba. This approval covers the described preparatory activities and is not comprehensive authorisation to operate a commercial uranium enrichment plant.
Commercial production would require further technical development, the permissions associated with the proposed processes and appropriate arrangements for nuclear safeguards. The company has not provided an approved commercial operating licence, a final financing package or a confirmed construction and commissioning timetable for the facility.
Quantum Leap Energy is a development-stage nuclear fuels company and has rights to proprietary isotope separation technologies, including the Aerodynamic Separation Process and Quantum Enrichment approach identified by ASP Isotopes. Their intended application within the proposed project remains subject to demonstration and the specific authorisations governing uranium-235 work; rights to technology do not establish commercial plant performance.
Large industrial facilities also depend on equipment procurement and integration. The partners intend for Necsa to enter into an engineering, procurement and construction arrangement with Quantum Leap Energy, drawing on the organisation’s existing nuclear engineering capability. That intended arrangement has not been reported as a completed construction contract with an agreed project cost and delivery schedule.
The proposed ownership structure determines the partners’ commercial roles but does not establish the amount of capital committed. Quantum Leap Energy will be responsible for arranging financing, while Necsa’s contributions will include site access and institutional support. The October filing contains no final investment decision or disclosed cost for a commercial-scale plant.
Safeguards and accounting requirements are fundamental to the operation of enrichment facilities. Operators must be able to account for nuclear material and demonstrate compliance with applicable legal and international obligations, while production equipment and procedures are subject to the controls relevant to the licensed activity. Necsa’s experience can support those tasks without replacing the decisions of the responsible authorities.
The proposed development could also create requirements for specialist industrial suppliers providing equipment, instruments, buildings and supporting services. The scale and timing of such procurement cannot be determined until engineering and financing advance, and the companies have not announced confirmed contracts for a complete facility or an employment forecast attributable to the venture.
ASP Isotopes operates other isotope-related businesses in South Africa, but the parent company’s existing activities involving lighter isotopes should not be confused with an operational HALEU plant. Producing one isotope product does not automatically qualify the technology, equipment or operating organisation for a different nuclear material and regulatory regime.
TerraPower’s offtake arrangements provide commercial context for the proposal. Their significance will ultimately depend on whether material meeting the necessary specifications can be produced under authorised conditions and delivered through the required fuel supply chain. The announcement contains no evidence of completed deliveries to TerraPower from Pelindaba.
The next milestones will be progress with the test bench refurbishment, the specific permissions needed for uranium-235 work, financing and detailed engineering arrangements. The binding agreement gives the partners a structure for pursuing those activities; it does not establish that commercial enrichment or HALEU fuel supply is already under way in South Africa.
